Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life. [PDF]
Chowdhury JM.
europepmc +1 more source
Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). [PDF]
Chakraborty D +9 more
europepmc +1 more source
Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services ...
Chakraborty D +7 more
doaj
Anti-VEGF therapy for posterior segment disorders: The story so far…. [PDF]
Chawla R.
europepmc +1 more source
From bench to bed: The evolution of anti-vascular endothelial growth factor therapies. [PDF]
Sen A, Kohli G, Agarwal A, Chauhan R.
europepmc +1 more source
Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]
Hamida JA +7 more
europepmc +1 more source
Ten-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. [PDF]
Kung YH, Peng KL, Shih LY, Wu TT.
europepmc +1 more source
Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead. [PDF]
Mishra C +4 more
europepmc +1 more source
Comparison of the effectiveness of ranibizumab monotherapy vs. combined panretinal photocoagulation on the regression of neovascularization in proliferative diabetic retinopathy. [PDF]
Wang Y, Wang L, Zheng Z, Xu J, Zhang Z.
europepmc +1 more source
Peep into anti-vascular endothelial growth factor. [PDF]
Verma L, Singh S, Ramachandran O.
europepmc +1 more source

